Literature DB >> 4009325

Clinical differences in chronic granulomatous disease in patients with cytochrome b-negative or cytochrome b-positive neutrophils.

R S Weening, L H Adriaansz, C M Weemaes, R Lutter, D Roos.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 4009325     DOI： 10.1016/s0022-3476(85)80626-0

Source DB:  PubMed          Journal:  J Pediatr        ISSN： 0022-3476            Impact factor:   4.406


× No keyword cloud information.
  11 in total

Review 1.  Neutrophil disorders and their management.

Authors:  R Lakshman; A Finn
Journal:  J Clin Pathol       Date:  2001-01       Impact factor: 3.411

2.  Prognosis of chronic granulomatous disease.

Authors:  A Finn; N Hadzić; G Morgan; S Strobel; R J Levinsky
Journal:  Arch Dis Child       Date:  1990-09       Impact factor: 3.791

Review 3.  Clinical manifestations of disease in X-linked carriers of chronic granulomatous disease.

Authors:  A C Battersby; A M Cale; D Goldblatt; A R Gennery
Journal:  J Clin Immunol       Date:  2013-11       Impact factor: 8.317

4.  Autosomal recessive chronic granulomatous disease associated with 18q-syndrome and end-stage renal failure due to Henoch-Schönlein nephritis.

Authors:  J Kimpen; R Van Damme-Lombaerts; G Van den Berghe; W Proesmans
Journal:  Eur J Pediatr       Date:  1991-03       Impact factor: 3.183

5.  Point mutations in the promoter region of the CYBB gene leading to mild chronic granulomatous disease.

Authors:  R S Weening; M De Boer; T W Kuijpers; V M Neefjes; W W Hack; D Roos
Journal:  Clin Exp Immunol       Date:  2000-12       Impact factor: 4.330

Review 6.  Interferon gamma-1b. A review of its pharmacology and therapeutic potential in chronic granulomatous disease.

Authors:  P A Todd; K L Goa
Journal:  Drugs       Date:  1992-01       Impact factor: 9.546

Review 7.  The molecular basis of chronic granulomatous disease.

Authors:  C Meischl; D Roos
Journal:  Springer Semin Immunopathol       Date:  1998

8.  Host defense molecule polymorphisms influence the risk for immune-mediated complications in chronic granulomatous disease.

Authors:  C B Foster; T Lehrnbecher; F Mol; S M Steinberg; D J Venzon; T J Walsh; D Noack; J Rae; J A Winkelstein; J T Curnutte; S J Chanock
Journal:  J Clin Invest       Date:  1998-12-15       Impact factor: 14.808

9.  Special article: chronic granulomatous disease in the United Kingdom and Ireland: a comprehensive national patient-based registry.

Authors:  L B K R Jones; P McGrogan; T J Flood; A R Gennery; L Morton; A Thrasher; D Goldblatt; L Parker; A J Cant
Journal:  Clin Exp Immunol       Date:  2008-05       Impact factor: 4.330

10.  Ozone production by amino acids contributes to killing of bacteria.

Authors:  Kouhei Yamashita; Takashi Miyoshi; Toshiyuki Arai; Nobuyuki Endo; Hiroshi Itoh; Keisuke Makino; Kiyomi Mizugishi; Takashi Uchiyama; Masataka Sasada
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-29       Impact factor: 11.205
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.